Darzalex (daratumumab)

P2, N=140, Active, not recruiting, PETHEMA Foundation | Not yet recruiting --> Active, not recruiting

Two patients presented interference in FCM analysis, supporting the penetration of daratumumab into the CSF...Flow-cytometry panels need to be optimized for plasma-cell detection, especially among patients treated with anti-CD38 antibodies. Identifying patients at risk remains crucial, but prognostic biomarkers such as IL-6 still require validation.

P2/3, N=153, Not yet recruiting, AstraZeneca AB

P2, N=41, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Jul 2026 --> Jul 2027 | Trial primary completion date: Jul 2026 --> Jul 2027

P1/2, N=300, Active, not recruiting, Karyopharm Therapeutics Inc | Recruiting --> Active, not recruiting

P2/3, N=38, Not yet recruiting, AstraZeneca AB

P1/2, N=16, Active, not recruiting, West Virginia University | Trial completion date: Feb 2026 --> Dec 2026 | Trial primary completion date: Feb 2026 --> Dec 2026

In newly diagnosed MM (NDMM), minimal residual disease (MRD)-adaptive consolidation with linvoseltamab in IMMUNOPLANT converted persistent MRD positivity to MRD negativity in all evaluable patients, supporting biologically guided treatment intensification...In early relapsed/refractory MM (RRMM), the pioneering phase III MajesTEC-3 trial demonstrated significant progression-free survival (PFS) and overall survival (OS) benefits with BsAb teclistamab plus daratumumab compared to other standard triplets, with response rates approaching those historically observed with chimeric antigen receptor (CAR) T cell therapy. A novel rational BsAb combination of BsAb elranatamab anda cereblon E3 ligase modulatory drug (CELMoD) iberdomide in MagnetisMM-30 showed promising synergy despite cytopenias and updates to combination BsAb targeting in RedirecTT-1 demonstrated major activity in difficult to treat extramedullary myeloma (EMM). First-in-human inMMyCAR data showcased the forefront of engineered immune strategies, by introducing an in vivo CAR-T product as a proof-of-concept platform, with tremendous potential to streamline the access to therapy. Collectively, these studies signal a shift toward earlier and adaptive immunotherapy in all phases of MM disease, while underscoring the importance of infection mitigation and long-term safety evaluation.

P3, N=494, Active, not recruiting, GlaxoSmithKline | Trial completion date: Jun 2026 --> Jun 2028

P3, N=72, Active, not recruiting, GlaxoSmithKline | Trial completion date: Jun 2026 --> Jun 2028

P3, N=24, Active, not recruiting, GlaxoSmithKline | Trial completion date: Jun 2026 --> Jun 2028

Daratumumab-mediated disruption of mitochondrial transfer reduced the mitochondrial content in MM cells, prevented the boost in OXPHOS, significantly impaired MM cell growth and migration, and mitigated drug-resistance. In conclusion, we reveal a crucial metabolic interplay between monocytes and MM cells within the BM microenvironment that promotes tumor growth and induces therapy resistance, providing the rationale for treatment strategies that combine targeting tumor metabolism with existing anti-MM agents.